✦ LIBER ✦

Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: The CAPPA-2 study

✍ Scribed by Morabito, Alessandro; Gebbia, Vittorio; Di Maio, Massimo; Cinieri, Saverio; Viganò, Maria Grazia; Bianco, Roberto; Barbera, Santi; Cavanna, Luigi; De Marinis, Filippo; Montesarchio, Vincenzo; Costanzo, Raffaele; Sandomenico, Claudia; Montanino, Agnese; Mancuso, Gianfranco; Russo, Paolo; Nacci, Angelo; Giordano, Pasqualina; Daniele, Gennaro; Piccirillo, Maria Carmela; Rocco, Gaetano; Gridelli, Cesare; Gallo, Ciro; Perrone, Francesco

Book ID: 122987491
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 930 KB
Volume: 81
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2013.04.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II randomized trial of gemcitabi

A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma

✍ Joaquín Casal Rubio; S. Vázquez; F. Vázquez; M. Amenedo; J. L. Fírvida; J. R. Me 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 255 KB

O-094 Paclitaxel and gemcitabine vs carb

O-094 Paclitaxel and gemcitabine vs carboplatin and gemcitabine. A multicenter, phase III randomized trial in patients with advanced inoperable Non-small cell lung cancer (NSCLC)

✍ Kosmidis, P.; Kalofonos, C.; Syrigos, K.; Skarlos, D.; Fountzilas, G.; Nicolaide 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 138 KB

Results of a Phase II Trial of Gemcitabi

Results of a Phase II Trial of Gemcitabine in Patients with Non–Small-Cell Lung Cancer and a Performance Status of 2

✍ Marcus A. Neubauer; Craig H. Reynolds; Marcos G. Joppert; Thomas Whittaker; Habi 📂 Article 📅 2005 🏛 CIG Media Group, LP. 🌐 English ⚖ 143 KB

Phase III Study of Erlotinib in Combinat

Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

✍ Gatzemeier, U.; Pluzanska, A.; Szczesna, A.; Kaukel, E.; Roubec, J.; De Rosa, F. 📂 Article 📅 2007 🏛 American Society of Clinical Oncology 🌐 English ⚖ 169 KB

Phase III Study of Erlotinib in Combinat

Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

✍ Gatzemeier, U.; Pluzanska, A.; Szczesna, A.; Kaukel, E.; Roubec, J.; De Rosa, F. 📂 Article 📅 2007 🏛 American Society of Clinical Oncology 🌐 English ⚖ 169 KB

## Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase, with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of chemotherapy. This phase III, randomized, double-blind, placebo-controlled, multicenter trial evaluated th

Commentary on “Interim Analysis of a Pha

Commentary on “Interim Analysis of a Phase III Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine vs. Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non–Small-Cell Lung Cancer (NSCLC)”

✍ Gregory A. Masters 📂 Article 📅 2000 🏛 CIG Media Group, LP. 🌐 English ⚖ 350 KB